February 20, 2026
In 2025, Morocco’s regulated medical-and-industrial program crossed a threshold the global market had been watching for: first legal exports under the country’s post‑Law 13‑21 framework—and a fast‑expanding pipeline of authorized products.
By September 2025, Moroccan authorities publicly reported approvals for 60+ (often cited as “67”) regulated products, reflecting a shift from early licensing to real commercial execution across cultivation cooperatives, processing, quality systems, and export logistics. For operators, that scale-up also signals a new phase of scrutiny: Good Agricultural and Collection Practices (GACP) at farm level, GMP-aligned manufacturing, batch testing, and traceability/serialization that can stand up to EU and APAC import regimes.
This article breaks down what “export readiness” looks like in Morocco for 2025–2026, focusing on ANRAC approvals, export permit mechanics, product categories moving through authorization, cooperative onboarding, and the compliance controls Morocco is using to reduce diversion risk while competing on quality and cost.
Informational only; not legal advice. Always verify requirements with ANRAC and destination-country authorities.
Morocco’s legal framework for regulated medical/industrial uses is anchored by Law 13‑21, implemented through decrees and administrative guidance. The operational regulator is the Agence Nationale de Réglementation des Activités relatives au Cannabis (ANRAC).
Key compliance reality for 2025–2026: ANRAC is not only a licensing body. It functions as the gatekeeper for the full lifecycle—cultivation authorization, movement controls, processing approvals, and export permissions—with an increasing emphasis on documented quality systems and auditable chain-of-custody.
External link: https://www.anrac.ma/
Three developments pushed Morocco from “framework” to “market”:
Exporting from Morocco is not a single permit—it is typically a stack of approvals that must align across the Moroccan side and the destination-country import clearance.
At a high level, exporters should expect the process to resemble the following compliance sequence.
Export readiness starts with licensing scope and site approvals. Depending on your role, ANRAC may require authorization for activities such as:
Practical takeaway: treat export as an extension of your licensed lifecycle. If your business model includes API, extract, or finished dose forms, ensure your authorizations and SOPs explicitly cover those operations.
Where Morocco has reported 67 approved products, businesses should interpret “product approvals” as an ANRAC-controlled pathway that can vary by category (for example, bulk inputs vs finished forms).
Exporters should validate:
If the destination market is the EU, the product authorization strategy must also map to EU expectations around GMP manufacturing, QP batch certification (where applicable), and local narcotics import rules.
Destination markets increasingly treat “medical supply chain” credibility as a GACP → GMP continuity story.
Export-linked cultivation should demonstrate:
For extracts, APIs, and finished forms, buyers and import authorities often require:
Note: “GMP” can mean different levels depending on destination (national GMP vs EU-GMP). If you are selling into the EU supply chain, buyers will typically expect EU‑GMP alignment for manufacturing sites, and GACP for cultivation.
Export shipments live or die by batch release.
A compliant export dossier typically includes:
Even if Morocco’s domestic minimums differ by category, destination-country importers often impose their own specifications. For 2025–2026, exporters should assume that EU buyers will benchmark against European Pharmacopeia concepts and local narcotics-medical frameworks.
Morocco’s diversion-control strategy relies heavily on chain-of-custody and trackable inventory.
Exporters should plan for:
Even when the destination market does not mandate a specific serialization schema, buyers increasingly request serialization-compatible packaging and digital traceability to support downstream compliance.
One of the most common export failures globally is treating import clearance as “the buyer’s problem.” In regulated medical channels, it is a shared compliance requirement.
Exporters should require documented evidence of:
In the EU, many supply chains require Qualified Person (QP) batch certification before release to market, which influences what documentation must accompany the shipment.
Public reporting in 2025 referenced approvals for 60+ / 67 products. While the exact list and category breakdown should be validated directly with ANRAC communications, operators should understand the typical “regulated product ladder” in emerging export markets.
Businesses should expect authorizations to cluster into:
The compliance gap between categories is significant:
For 2025–2026, Morocco’s competitive edge will depend on how quickly operators can produce consistent, specification-driven outputs at scale.
Morocco’s model relies heavily on licensed cultivation through farmer cooperatives, particularly in traditional growing regions. For compliance leaders, cooperative integration is both a supply opportunity and a systems challenge.
Operators working with cooperatives should expect requirements such as:
To support export, contract farming arrangements should include compliance clauses covering:
Practical takeaway: If you cannot audit it, you cannot export it. Contract farming must be written to allow field inspections, sampling, and corrective actions.
Because Morocco is competing against established exporters, buyers will evaluate not only price and quality, but also the integrity of the supply chain.
Programs seeking international credibility commonly implement:
For exporters, diversion controls are not merely “security.” They’re a documented compliance narrative that convinces importers, banks, insurers, and regulators that Moroccan supply can be trusted.
Morocco has potential structural advantages: proximity to Europe, agricultural experience, and the ability to organize cultivation through cooperatives. But EU and many APAC channels are unforgiving on quality systems.
If your target is the EU (directly or via EU-linked supply chains), prioritize:
External context link (EU GMP baseline): https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
APAC markets vary widely. Many require:
The operational lesson: design your QMS for the most stringent target market you plan to serve.
Use this as an internal readiness guide for export operations.
If you’re building or investing in Morocco’s regulated supply chain, the winning edge in 2025–2026 will be a repeatable compliance system: licensing coverage, product authorization strategy, GACP/GMP readiness, batch documentation, and shipment traceability.
Use https://cannabisregulations.ai/ to track regulatory updates, build compliant SOP frameworks, and pressure-test your export dossiers before they hit ANRAC review or destination-country import clearance.
In 2025, Morocco’s regulated medical-and-industrial program crossed a threshold the global market had been watching for: first legal exports under the country’s post‑Law 13‑21 framework—and a fast‑expanding pipeline of authorized products.
By September 2025, Moroccan authorities publicly reported approvals for 60+ (often cited as “67”) regulated products, reflecting a shift from early licensing to real commercial execution across cultivation cooperatives, processing, quality systems, and export logistics. For operators, that scale-up also signals a new phase of scrutiny: Good Agricultural and Collection Practices (GACP) at farm level, GMP-aligned manufacturing, batch testing, and traceability/serialization that can stand up to EU and APAC import regimes.
This article breaks down what “export readiness” looks like in Morocco for 2025–2026, focusing on ANRAC approvals, export permit mechanics, product categories moving through authorization, cooperative onboarding, and the compliance controls Morocco is using to reduce diversion risk while competing on quality and cost.
Informational only; not legal advice. Always verify requirements with ANRAC and destination-country authorities.
Morocco’s legal framework for regulated medical/industrial uses is anchored by Law 13‑21, implemented through decrees and administrative guidance. The operational regulator is the Agence Nationale de Réglementation des Activités relatives au Cannabis (ANRAC).
Key compliance reality for 2025–2026: ANRAC is not only a licensing body. It functions as the gatekeeper for the full lifecycle—cultivation authorization, movement controls, processing approvals, and export permissions—with an increasing emphasis on documented quality systems and auditable chain-of-custody.
External link: https://www.anrac.ma/
Three developments pushed Morocco from “framework” to “market”:
Exporting from Morocco is not a single permit—it is typically a stack of approvals that must align across the Moroccan side and the destination-country import clearance.
At a high level, exporters should expect the process to resemble the following compliance sequence.
Export readiness starts with licensing scope and site approvals. Depending on your role, ANRAC may require authorization for activities such as:
Practical takeaway: treat export as an extension of your licensed lifecycle. If your business model includes API, extract, or finished dose forms, ensure your authorizations and SOPs explicitly cover those operations.
Where Morocco has reported 67 approved products, businesses should interpret “product approvals” as an ANRAC-controlled pathway that can vary by category (for example, bulk inputs vs finished forms).
Exporters should validate:
If the destination market is the EU, the product authorization strategy must also map to EU expectations around GMP manufacturing, QP batch certification (where applicable), and local narcotics import rules.
Destination markets increasingly treat “medical supply chain” credibility as a GACP → GMP continuity story.
Export-linked cultivation should demonstrate:
For extracts, APIs, and finished forms, buyers and import authorities often require:
Note: “GMP” can mean different levels depending on destination (national GMP vs EU-GMP). If you are selling into the EU supply chain, buyers will typically expect EU‑GMP alignment for manufacturing sites, and GACP for cultivation.
Export shipments live or die by batch release.
A compliant export dossier typically includes:
Even if Morocco’s domestic minimums differ by category, destination-country importers often impose their own specifications. For 2025–2026, exporters should assume that EU buyers will benchmark against European Pharmacopeia concepts and local narcotics-medical frameworks.
Morocco’s diversion-control strategy relies heavily on chain-of-custody and trackable inventory.
Exporters should plan for:
Even when the destination market does not mandate a specific serialization schema, buyers increasingly request serialization-compatible packaging and digital traceability to support downstream compliance.
One of the most common export failures globally is treating import clearance as “the buyer’s problem.” In regulated medical channels, it is a shared compliance requirement.
Exporters should require documented evidence of:
In the EU, many supply chains require Qualified Person (QP) batch certification before release to market, which influences what documentation must accompany the shipment.
Public reporting in 2025 referenced approvals for 60+ / 67 products. While the exact list and category breakdown should be validated directly with ANRAC communications, operators should understand the typical “regulated product ladder” in emerging export markets.
Businesses should expect authorizations to cluster into:
The compliance gap between categories is significant:
For 2025–2026, Morocco’s competitive edge will depend on how quickly operators can produce consistent, specification-driven outputs at scale.
Morocco’s model relies heavily on licensed cultivation through farmer cooperatives, particularly in traditional growing regions. For compliance leaders, cooperative integration is both a supply opportunity and a systems challenge.
Operators working with cooperatives should expect requirements such as:
To support export, contract farming arrangements should include compliance clauses covering:
Practical takeaway: If you cannot audit it, you cannot export it. Contract farming must be written to allow field inspections, sampling, and corrective actions.
Because Morocco is competing against established exporters, buyers will evaluate not only price and quality, but also the integrity of the supply chain.
Programs seeking international credibility commonly implement:
For exporters, diversion controls are not merely “security.” They’re a documented compliance narrative that convinces importers, banks, insurers, and regulators that Moroccan supply can be trusted.
Morocco has potential structural advantages: proximity to Europe, agricultural experience, and the ability to organize cultivation through cooperatives. But EU and many APAC channels are unforgiving on quality systems.
If your target is the EU (directly or via EU-linked supply chains), prioritize:
External context link (EU GMP baseline): https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
APAC markets vary widely. Many require:
The operational lesson: design your QMS for the most stringent target market you plan to serve.
Use this as an internal readiness guide for export operations.
If you’re building or investing in Morocco’s regulated supply chain, the winning edge in 2025–2026 will be a repeatable compliance system: licensing coverage, product authorization strategy, GACP/GMP readiness, batch documentation, and shipment traceability.
Use https://cannabisregulations.ai/ to track regulatory updates, build compliant SOP frameworks, and pressure-test your export dossiers before they hit ANRAC review or destination-country import clearance.
